ReviewAnnals of the American Thoracic Society2015
Metabolomics: Applications and Promise in Mycobacterial Disease.
Review in Annals of the American Thoracic Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Metabolomics and Artificial Intelligence (AI) assisted metabolomics in the diagnosis of non-tuberculous mycobacterial infections: progress and challenges.New microbes and new infections · 2026Review
- Discovery of urinary biosignatures for tuberculosis and nontuberculous mycobacteria classification using metabolomics and machine learning.Scientific reports · 2024Article
- Artefact Profiling: Panomics Approaches for Understanding the Materiality of Written Artefacts.Molecules (Basel, Switzerland) · 2023Review
- Therapeutic Potentials of Immunometabolomic Modulations Induced by Tuberculosis Vaccination.Vaccines · 2022Review
- Using Omics to Study Leprosy, Tuberculosis, and Other Mycobacterial Diseases.Frontiers in cellular and infection microbiology · 2022Review
- Tuberculous Granuloma: Emerging Insights From Proteomics and Metabolomics.Frontiers in neurology · 2022Review
- Metabolomic Changes in Naturally MAP-Infected Holstein-Friesian Heifers Indicate Immunologically Related Biochemical Reprogramming.Metabolites · 2021Article
- Urine NMR-based TB metabolic fingerprinting for the diagnosis of TB in children.Scientific reports · 2021Article
- Usnic Acid Treatment Changes the Composition of Mycobacterium tuberculosis Cell Envelope and Alters Bacterial Redox Status.mSystems · 2021Article
- Dissecting Host-Pathogen Interactions in TB Using Systems-Based Omic Approaches.Frontiers in immunology · 2021Review
- Discovery and validation of an NMR-based metabolomic profile in urine as TB biomarker.Scientific reports · 2020Article
- Mycobacterium tuberculosis curli pili (MTP) deficiency is associated with alterations in cell wall biogenesis, fatty acid metabolism and amino acid synthesis.Metabolomics : Official journal of the Metabolomic Society · 2020Article
- Comprehensive Examination of the Mouse Lung Metabolome FollowingJournal of proteome research · 2020Article
- Article
- Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.Accounts of chemical research · 2019Review
- Article
- The crucial role of multiomic approach in cancer research and clinically relevant outcomes.The EPMA journal · 2018Review
- Recent Trends in System-Scale Integrative Approaches for Discovering Protective Antigens Against Mycobacterial Pathogens.Frontiers in genetics · 2018Review
- UPLC-MS for metabolomics: a giant step forward in support of pharmaceutical research.Drug discovery today · 2017Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors.
Funding
Abstract
Until recently, the study of mycobacterial diseases was trapped in culture-based technology that is more than a century old. The use of nucleic acid amplification is changing this, and powerful new technologies are on the horizon. Metabolomics, which is the study of sets of metabolites of both the bacteria and host, is being used to clarify mechanisms of disease, and can identify changes leading to better diagnosis, treatment, and prognostication of mycobacterial diseases. Metabolomic profiles are arrays of biochemical products of genes in their environment. These complex patterns are biomarkers that can allow a more complete understanding of cell function, dysfunction, and perturbation than genomics or proteomics. Metabolomics could herald sweeping advances in personalized medicine and clinical trial design, but the challenges in metabolomics are also great. Measured metabolite concentrations vary with the timing within a condition, the intrinsic biology, the instruments, and the sample preparation. Metabolism profoundly changes with age, sex, variations in gut microbial flora, and lifestyle. Validation of biomarkers is complicated by measurement accuracy, selectivity, linearity, reproducibility, robustness, and limits of detection. The statistical challenges include analysis, interpretation, and description of the vast amount of data generated. Despite these drawbacks, metabolomics provides great opportunity and the potential to understand and manage mycobacterial diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.